经鼻持续气道正压通气对阻塞性睡眠呼吸暂停综合征的综合疗效

经鼻持续气道正压通气（CPAP）是目前治疗阻塞性呼吸暂停综合征（OSAS）最有效的内科治疗方法,通过向气道内增加一定程度的正压,保持上气道通畅,消除患者夜间缺氧,改善患者夜间打鼾,白天嗜睡等临床症状,恢复睡眠结构,并治疗与此相关的各系统疾病,提高患者长期的生活质量。     

Arbitrary-pressure continuous positive airway pressure for obstructive sleep apnea syndrome

Current resources are inadequate to meet the demand for polysomnography, resulting in long waiting lists. This study aimed to evaluate the role of arbitrary-pressure continuous positive airway pressure (CPAP) as a method to reduce delays in commencing treatment. The study was of an open, randomized, parallel design. Ninety-one subjects with obstructive sleep apnea syndrome were randomized to either arbitrary-pressure CPAP based on body mass index before treatment polysomnography or to CPAP at settings determined by polysomnography. Both interventions resulted in similar improvements in clinical outcomes as determined by Epworth Sleepiness Score, Short Form-36 Quality of Life questionnaire, objective compliance, and subjective attitudes to treatment. There was higher sleep efficiency at treatment polysomnography in the group commenced at arbitrary pressure (81.8 +/- 10.1% [mean +/- SD] compared with 72.2 +/- 18.0%, p = 0.01). Subjects unable to tolerate CPAP were identified by the use of arbitrary pressure, leading to a reduction in the proportion of "wasted" treatment polysomnograms (studies performed in subjects not persisting with treatment) relative to commencing therapy after treatment polysomnography (3 of 39 compared with 12 of 35, p = 0.01). This approach to initiating treatment with CPAP appears feasible when there are long waiting lists for polysomnography.     

Effect of continuous positive airway pressure vs placebo continuous positive airway pressure on sleep quality in obstructive sleep apnea

STUDY OBJECTIVES: Continuous positive airway pressure (CPAP) therapy has become the treatment of choice for obstructive sleep apnea (OSA). However, the efficacy of CPAP therapy has not been evaluated against a suitable control. We investigated the effectiveness of CPAP therapy in improving sleep quality in patients with OSA. We hypothesized that CPAP improves sleep quality. PATIENTS: Forty-eight CPAP-naive OSA patients were evaluated. None were receiving antihypertensive medications, and none had major medical illnesses. DESIGN: Patients were randomized to receive either CPAP or placebo CPAP (CPAP at an ineffective pressure) for 7 days in a double-blind fashion. Forty-one patients completed the protocol. Sleep quality variables, arousals, sleep arterial oxygen saturation (SaO(2)), and respiratory disturbance index (RDI) were assessed at baseline, after 1 day of treatment, and after 7 days of treatment. Repeated measures analysis of variance was used to evaluate the effects of treatment, time, and the interaction of the two. RESULTS: As expected, CPAP lowered RDI and number of arousals, and increased SaO(2) over time (p = 0.001). Contrary to expectations, both CPAP and placebo CPAP had comparable effects on sleep quality as assessed by sleep architecture, sleep efficiency, total sleep time, and wake after sleep onset time. CONCLUSIONS: This study confirms the effectiveness of CPAP in lowering the number of arousals and the RDI, and in raising SaO(2). However, our data suggest that short-term CPAP is no different than placebo in improving sleep architecture. Further evaluation of the effectiveness of CPAP using a suitable placebo CPAP in prospective randomized studies is needed     

Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome

PURPOSE: Obstructive sleep apnea syndrome is common in middle-aged men and may be associated with an increased risk of cardiovascular disease. We investigated the effect of nasal continuous positive airway pressure (CPAP) treatment on levels of soluble cell adhesion molecules-which have been shown to be associated with the development of atherosclerosis-in these patients. SUBJECTS AND METHODS: We studied 23 patients with obstructive sleep apnea syndrome diagnosed by polysomnography who were treated with nasal CPAP. Serum soluble intercellular adhesion molecule-1, E-selectin, and vascular cell adhesion molecule-1 levels were measured before nasal CPAP was started, and after 3 or 4 days (n = 19), 1 month (n = 23), or 6 months (n = 11) of treatment. RESULTS: After 3 to 4 days of nasal CPAP therapy, the mean (+/- SD) soluble E-selectin level had decreased from 89 +/- 44 ng/mL to 69 +/- 28 ng/mL (P = 0.002). After 1 month, the soluble intercellular adhesion molecule-1 level had decreased from 311 +/- 116 ng/mL to 249 +/- 74 ng/mL (P = 0.02). After 6 months, soluble vascular cell adhesion molecule-1 levels had not changed significantly, while the mean soluble intercellular adhesion molecule-1 level (212 +/- 59 ng/mL) had decreased further (P = 0.02). Before treatment, soluble intercellular adhesion molecule-1 levels and the apnea and hypopnea index were correlated (r = 0.43, P = 0.04). CONCLUSIONS: Obstructive sleep apnea and hypopnea have a significant adverse effect on serum soluble cell adhesion molecule-1 levels that may be reduced by nasal CPAP treatment.     

持续气道正压治疗对阻塞性睡眠呼吸暂停患者夜间多尿症状的影响

目的研究持续气道正压（CPAP）治疗对阻塞性睡眠呼吸暂停综合征（OSAS）患者夜间多尿症状的影响。方法15例多导睡眠图（PSG）确诊的OSAS患者,记录CPAP治疗前后的夜尿次数、夜尿量、夜尿渗透压和夜尿钠排泄量,测定其中8例患者治疗前后夜间（23时、02时、05时）心钠素（ANP）水平。结果(1)CPAP治疗后OSAS患者夜尿次数明显减少（P<0.01）。(2)夜尿量由(0.078±0.017)L/h降至(0.052±0.011)L/h（P<0.01）。(3)CPAP治疗后OSAS患者夜尿渗透压由(381±96)mmol/L明显增高至(570±169)mmol/L（P<0.05）。(4)CPAP治疗后OSAS患者夜尿钠的排泄量由(1.16±0.35)mmol/h降至(0.63±0.13)mmol/h（P<0.01）。(5)8例患者CPAP治疗前后的夜间ANP平均水平分别为(146±14)ng/L和(106±10)ng/L,两者相比差异有显著性(P<0.01)。(6)8例测定ANP患者在CPAP治疗后ANP降低值与该患者夜尿量降低值、夜尿渗透压增高值、夜尿钠排泄量减少值均有显著的正相关,相关系数分别为0.82、0.84、0.81(P均<0.01)。结论CPAP治疗可明显减少OSAS患者夜尿次数和夜尿量,减少夜尿钠排泄量,增加夜尿渗透压,这些改变可能与ANP水平降低有关。     

Effect of continuous positive airway pressure therapy on 24-hour blood pressure in patients with obstructive sleep apnea syndrome

BACKGROUND: Patients with obstructive sleep apnea syndrome (OSAS) are subject to an increased cardiovascular morbidity including systemic hypertension. Little is known about the effects of treatment with nasal continuous positive airway pressure (CPAP) on systemic hypertension. METHODS: Automated ambulatory 24-h blood pressure (BP) monitoring was performed in 88 consecutive patients who were referred for evaluation of snoring or suspected OSAS. In addition, the long-term effects of CPAP therapy on 24-h BP were assessed. RESULTS: A total of 62 patients had OSAS and 26 habitual snoring. Patients with OSAS had significantly higher mean arterial BP values than snorers (102.7 +/- 10.7 v 94.0 +/- 10.2 mm Hg; P < .01). Multiple stepwise linear regression analysis disclosed that the degree of systemic hypertension was independently associated with the severity of OSAS as determined by the apnea/hypopnea index (R = 0.43; P < .001), but not with age, body mass index, or smoking habits. Of the 62 patients with OSAS, 52 were treated with CPAP and reevaluated after 9 months. The CPAP resulted in a significant decrease in mean arterial BP (from 103.7 +/- 10.4 to 99.1 +/- 10.8 mm Hg; P < .05). For those patients with systemic hypertension whose BP improved with CPAP therapy, 24-h mean pulse pressure at baseline (r = -0.36; P < .05) as well as average heart rate during the day (r = -0.35; P < .05) turned out as predictors. CONCLUSIONS: Obstructive sleep apnea syndrome contributes, at least in part, to the development of systemic hypertension, and CPAP may improve BP values in treated OSAS patients. Predictors of a beneficial CPAP effect on BP are a high heart rate and a high pulse pressure before treatment.     

Effect of nasal continuous positive airway pressure in uncontrolled nocturnal asthmatic patients with obstructive sleep apnea syndrome

The mechanisms of nocturnal asthma are intimately related to circadian rhythms, which influence inflammatory cells and mediators, hormone levels and cholinergic tone. Nocturnal airway narrowing in asthma is sometimes associated with sleep disorders, such as obstructive sleep apnea syndrome (OSAS). The aims of this study were to evaluate the association of nocturnal asthma and OSAS, and investigate the influence of continuous positive airway pressure (CPAP) therapy to improve nighttime symptoms in asthmatic patients with OSAS. Forty-three asthmatic patients who had nocturnal symptoms in spite of the optimal medical treatment according to the Global Initiative for Asthma guidelines and associated with snoring were studied. Pulmonary function tests (PFTs), asthma nighttime symptom scores, and polysomnography were performed on all patients. We treated the patients with an apnea-hypopnea index (AHI) 15 (moderate-severe OSAS) (n=16) with CPAP during 2 months. After 2 months, PFT, asthma nighttime symptom scores were reperformed. There was no significant difference in PFT values before and after CPAP treatment in OSAS patients. Asthma nighttime symptom scores were improved significantly (P<0.05) after CPAP treatment. In conclusion, in some patients with nocturnal asthma, OSAS may be responsible disease for nocturnal symptoms. In this condition, CPAP improves nocturnal symptoms without amelioration in PFT abnormalities.     

Influence of gender on continuous positive airway pressure requirements in patients with obstructive sleep apnea syndrome

Introduction  

Gender differences have been noted in key aspects of upper airway physiology and pathophysiology of obstructive sleep apnea (OSA). We postulate that these will lead to disparities in pharyngeal collapsibility and, consequently, positive airway pressure requirements of patients with OSA.     

Effect of continuous positive airway pressure therapy on infectious complications in patients with obstructive sleep apnea syndrome.

BACKGROUND: Nasal continuous positive airway pressure (CPAP) is a well-established, widely used and effective treatment of obstructive sleep apnea syndrome (OSAS). Unfortunately, side effects are frequent during CPAP treatment. OBJECTIVES: Little is known about the effects of CPAP on infectious complications in patients with OSAS. METHODS: We retrospectively analyzed the kinds and rate of infections of the upper airway in 246 consecutive patients (mean age, 59.7 years) with polysomnographically verified OSAS using CPAP with or without a heated humidifier and compared them with OSAS patients who received non-CPAP therapy. RESULTS: Of the 246 patients, 40 received conservative therapy and 206 CPAP treatment, 36 of them with a heated humidifier. The mean follow-up period of the study group was 165.4 +/- 92.1 weeks and did not differ between the three groups. Infectious diseases were frequent in all three groups, but patients using CPAP without humidifier suffered from upper airway infections significantly more frequently than controls (42.9 vs. 25%; p < 0.05), and more patients on CPAP therapy with humidifier than controls (22.2 vs. 2.5%; p < 0.01) reported an increased rate of upper airway infections since initiation of CPAP therapy or diagnosis of OSAS. Especially patients using a hot water bath humidifier who cleaned their devices inadequately had significantly more upper airway infections since diagnosis (57.1 vs. 20%; p < 0.05) or during the past 6 months (52.4 vs. 13.3%; p < 0.05) than patients who regularly cleaned CPAP machines, humidifiers and ventilatory circuits. CONCLUSIONS: Our results suggest that patients using CPAP therapy either with or without heated humidity seem to be at an increased risk of upper airway infections compared to conservatively treated patients.     

持续气道正压通气对老年阻塞性睡眠呼吸暂停患者血栓前状态的影响

目的：探讨阻塞性睡眠呼吸暂停综合征(OSAS)老年患者的血栓前状态及经鼻持续气道正压通气(nCPAP)治疗对其影响。方法：选择16例中或重度OSAS老年患者(OSAS组)给予nCPAP治疗，分别于治疗前及治疗30d时的早晨(6：00)及午后(16：00)检测红细胞压积(HCT)、血小板聚集率(PAG)、血液黏滞度(WBV)、血浆纤维蛋白原(Fng)、凝血酶原时间(PT)和部分凝血活酶时间(APTT)。结果：OSAS患者nCPAP治疗前早晨与午后相比，HCT、WBV、血浆Fng及PAG均明显增高，PT及APTT缩短。经nCPAP治疗30d时各项指标在早晨与午后已无明显差异；与治疗前早晨相比，治疗30d早晨的HCT、WBV、PAG、血浆Fng水平均明显降低，且PT及APTT明显延长；与治疗前午后相比，治疗30d时午后的HCT、PAG明显降低，PT及APTT显著延长。结论：OSAS老年患者存在着明显的血栓前状态，nCPAP治疗对其有良好的防治作用。     

Positional treatment vs continuous positive airway pressure in patients with positional obstructive sleep apnea syndrome

OBJECTIVES: The aim of this study was to compare the relative efficacy of continuous positive airway pressure (CPAP) and positional treatment in the management of positional obstructive sleep apnea (OSA), using objective outcome measures. DESIGN: A prospective, randomized, single blind crossover comparison of CPAP and positional treatment for 2 weeks each. SETTING: A university teaching hospital. PATIENTS: Thirteen patients with positional OSA, aged (mean+/-SD) 51+/-9 years, with an apnea-hypopnea index (AHI) of 17+/-8. MEASUREMENTS: (1) Daily Epworth Sleepiness Scale scores; (2) overnight polysomnography, an objective assessment of sleep quality and AHI; (3) maintenance of wakefulness testing; (4) psychometric test battery; (5) mood scales; (6) quality-of-life questionnaires; and (7) individual patient's treatment preference. RESULTS: Positional treatment was highly effective in reducing time spent supine (median, 0; range, 0 to 32 min). The AHI was lower (mean difference, 6.1; 95% confidence interval [CI], 2 to 10.2; p = 0.007), and the minimum oxygen saturation was higher (4%; 95% CI, 1% to 8%; p = 0.02) on CPAP as compared with positional treatment. There was no significant difference, however, in sleep architecture, Epworth Sleepiness Scale scores, maintenance of wakefulness testing sleep latency, psychometric test performance, mood scales, or quality-of-life measures. CONCLUSION: Positional treatment and CPAP have similar efficacy in the treatment of patients with positional OSA.     

Nasal continuous positive airway pressure therapy in obstructive sleep apnea syndrome]

Sixteen patients (male: 14, female: 2, 41-72 yrs, mean 57.5 yrs) with OSAS were treated by nCPAP in our hospital since 1987. Respiratory disturbance index ranged from 16.5 to 83.1. The longest apnea duration was 35.0-120.5 seconds before the treatment. Two patients were treated with Sleep Easy III (Respironics Inc.) and others with a home made instruments. nCPAP was set at a pressure of 5 to 10 cm H2O. 12 patients (75%) tolerated the device but 4(25%) did not. Polysomnographic parameters before and after nCPAP therapy were compared. The longest apnea duration was 63.1 +/- 23.5 to 40.9 +/- 27.4 seconds (P less than 0.001) and the lowest saturation oxygen was 55.1 +/- 20.4% to 71.4 +/- 18.6% (P less than 0.05). The sleep structure improved but not significant statistically. One of them used nCPAP at home for more than two. years and showed a good long term effect. We concluded that nCPAP is an effective and safe treatment for OSAS. However, patients may be uncomfortable because of the wearing of the nasal mask during sleep.     

持续气道正压通气治疗对OSAHS患者血液流变学的影响

目的探讨阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者经鼻持续气道正压通气(ncpap)治疗对其血液流变学指标的影响。方法随机选择我科确诊为中度或重度OSAHS的患者30例,其中男20例,女10例,年龄45~68岁,平均年龄(58±3)岁,治疗前14d内未服用过非甾体类消炎药及阿斯匹林,潘生丁等抗凝剂,并排除其它呼吸系疾病、紫绀性先心病、肾脏疾病及原发性红细胞增多症,分别于治疗前及治疗30d后检测血细胞比容、全血比粘度(高切度、中切度、低切度),红细胞聚集指数。结果治疗后血细胞比容、全血比粘度(高切度、中切度、低切度)、红细胞聚集指数较治疗前显著降低(P<0.01)。结论OSAHS存在显著血栓栓塞高危因素,ncpap对其有明显防治作用。     

Efficacy of continuous positive airway pressure on arrhythmias in obstructive sleep apnea patients

The purpose of this study was to determine the relationship between obstructive sleep apnea (OSA) and cardiovascular disorders in a large Japanese population, and to assess the efficacy of continuous positive airway pressure (CPAP) in the treatment of OSA-associated arrhythmias. The study population comprised 1394 Japanese subjects (1086 men and 308 women) who were divided into four groups on the basis of polysomnography (PSG) analysis as follows: the no sleep apnea (N-SA) group (n = 44, apnea-hypopnea index [AHI] < 5), the mild OSA (Mi-OSA) group (n = 197, 5 < AHI < 15), the moderate OSA (Mo) group (n = 368, 15 < AHI < 30), and severe OSA (SOSA) group (n = 785, AHI < 30). The following baseline characteristics were significantly associated with OSA: age (P < 0.001), gender (P < 0.001), body mass index (P < 0.001), hypertension (P < 0.001), diabetes (P = 0.009), and hyperlipidemia (P = 0.013). In the OSA group, PSG revealed the predominance of paroxysmal atrial fibrillation (PAF) (P = 0.051), premature atrial complex short run (P < 0.005), premature ventricular complex (PVC, P = 0.004), sinus bradycardia (P = 0.036), and sinus pause (arrest >2 s, P < 0.001) during the PSG recording. A total of 316 patients from the group underwent CPAP titration and were then re-evaluated. Continuous positive airway pressure therapy significantly reduced the occurrences of PAF (P < 0.001), PVC (P = 0.016), sinus bradycardia (P = 0.001), and sinus pause (P = 0.004). The results of this study demonstrate a significant relationship between OSA and several cardiac disorders, and also demonstrate the efficacy of CPAP in preventing OSA-associated arrhythmias in a large population of Japanese patients.     

Prediction of continuous positive airway pressure in obstructive sleep apnea

Continuous positive airway pressure (CPAP) prediction formulas can potentially simplify the treatment of obstructive sleep apnea (OSA). However, they can be difficult to derive and validate. We tested a statistical method to derive and validate a CPAP prediction formula using the same sample population. Seventy-six OSA patients underwent polysomnography and CPAP titration. Anthropometric measures, sleep parameters, and the Epworth sleepiness scale (ESS) were evaluated as predictors. All subsets regression was used to determine the optimum number of variables in the model. The Bayes information criterion was used to find the best-fit model. The model was then evaluated by a tenfold cross-validation procedure. Subjects were obese (BMI 31.3 ± 5.4) and had significant daytime somnolence (ESS 11.9 ± 5). Mean respiratory disturbance index (RDI) was 53.5 ± 31.3. The ESS was not predictive of titrated CPAP. The best-fit model included three variables (CPAP_pred = 30.8 + RDI × 0.03 − nadir saturation × 0.05 − mean saturation × 0.2). This model explained 67% of the variance. Our data and the literature suggest that a combination of two to three factors is predictive of titrated CPAP: RDI, oxyhemoglobin saturation, and obesity. Except for RDI, the specific factors vary in each population. A CPAP prediction formula that explains a high proportion of the titrated CPAP variance can be easily derived from parameters measured during the diagnostic work-up of OSA patients using a unique statistical model that allows derivation and validation of the formula in the same test population.